Robert Dickey IV

Mr. Dickey is an accomplished C-level executive with more than 20 years of experience leading life science and medical device companies, both private and public, ranging from early-stage development to commercial operations. He has served as CFO to multiple companies, including Motif Bio (NASDAQ/AIM: MTFB), Tyme Technologies, Inc. (NASDAQ: TYME), BeyondSpring Pharmaceuticals, Inc. (NASDAQ: BYSI) and NeoStem, Inc. – now Caladrius Biosciences, Inc. (NASDAQ: CLBS). He previously spent nearly 20 years in investment banking at Lehman Brothers and Legg Mason. Mr. Dickey is experienced in all stages of the corporate life cycle, including start-up operations, high growth, turnarounds and exit strategies. His expertise includes building organizations, public and private financings, mergers and acquisitions, partnering/licensing transactions, project management and Chapter 11 reorganizations, as well as interactions with boards, venture capitalists, shareholders and Wall Street. He holds an AB from Princeton University and a MBA from The Wharton School, University of Pennsylvania.